The Wall Street Analyst Forum has been sponsoring analyst conferences in New York, Boston, and London since 1989, involving over 2,500 presenting NYSE/NASDAQ/AMEX corporations and the attendance of more than 15,000 analyst/portfolio managers.

Mr. Minogue will present the company's progress towards its goals for fiscal year 2005, provide an overview of the growing bridge to recovery market for circulatory support applications and speak about future product development for temporary circulatory support and the Company's implantable replacement heart, the AbioCor.

The presentation will be simultaneously webcast at 9:00 a.m. ET at the following web address: http://www.shareholder.com/wsaf/medialist.cfm. A link will also be available at www.abiomed.com.

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company’s AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial.

###

Media Contact:
Andrea tenBroek
Communications Specialist
(978) 646-1419
mediarelations@abiomed.com